{"id":"abx464","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABX464 acts as an RNA splicing modulator that selectively enhances the production of anti-inflammatory protein variants, particularly affecting immune response pathways. By shifting the balance toward anti-inflammatory isoforms, it reduces excessive immune activation and inflammation. This mechanism is designed to restore immune homeostasis in inflammatory and infectious diseases.","oneSentence":"ABX464 is a small molecule that modulates RNA splicing to promote the production of anti-inflammatory isoforms of proteins involved in immune regulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:04.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (Crohn's disease)"},{"name":"HIV infection"}]},"trialDetails":[{"nctId":"NCT03760003","phase":"PHASE2","title":"Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-08-13","conditions":"Ulcerative Colitis","enrollment":355},{"nctId":"NCT04393038","phase":"PHASE2, PHASE3","title":"ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19","status":"TERMINATED","sponsor":"Abivax S.A.","startDate":"2020-07-01","conditions":"COVID-19","enrollment":509},{"nctId":"NCT04049448","phase":"PHASE2","title":"Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-10-25","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT05535946","phase":"PHASE3","title":"ABTECT - Maintenance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abivax S.A.","startDate":"2023-01-16","conditions":"Ulcerative Colitis","enrollment":1116},{"nctId":"NCT05507203","phase":"PHASE3","title":"ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2022-10-10","conditions":"Ulcerative Colitis","enrollment":639},{"nctId":"NCT05507216","phase":"PHASE3","title":"ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2022-12-21","conditions":"Ulcerative Colitis","enrollment":636},{"nctId":"NCT05177835","phase":"PHASE2","title":"Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abivax S.A.","startDate":"2021-12-03","conditions":"Ulcerative Colitis","enrollment":203},{"nctId":"NCT04023396","phase":"PHASE2","title":"Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2020-01-13","conditions":"Ulcerative Colitis","enrollment":217},{"nctId":"NCT03368118","phase":"PHASE2","title":"Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2018-01-20","conditions":"Ulcerative Colitis","enrollment":22},{"nctId":"NCT02735863","phase":"PHASE2","title":"ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2016-05","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT03905109","phase":"PHASE2, PHASE3","title":"Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients","status":"WITHDRAWN","sponsor":"Abivax S.A.","startDate":"2022-09-19","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT03093259","phase":"PHASE2","title":"ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2017-11-16","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT02792686","phase":"PHASE1","title":"ABX464 First in Man Study","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2014-03","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT02990325","phase":"PHASE1, PHASE2","title":"A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2017-03-27","conditions":"HIV Infections, Health Volunteers","enrollment":36},{"nctId":"NCT03813199","phase":"PHASE2","title":"Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-07-04","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05032560","phase":"PHASE1","title":"Safety and Pharmacokinetics Study in Healthy Japanese Volunteers","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2021-09-27","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT05121714","phase":"PHASE1","title":"Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2020-12-17","conditions":"Healthy","enrollment":59},{"nctId":"NCT02452242","phase":"PHASE2","title":"Safety, PK and PD Study of ABX464 in Untreated HIV Patients","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2015-01","conditions":"Human Immunodeficiency Virus Infections","enrollment":70},{"nctId":"NCT02731885","phase":"PHASE1","title":"Food Effect on Pharmacokinetic Parameters of ABX464","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2014-09","conditions":"Healthy Volunteers","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Obefazimod"],"phase":"phase_3","status":"active","brandName":"ABX464","genericName":"ABX464","companyName":"Abivax S.A.","companyId":"abivax-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABX464 is a small molecule that modulates RNA splicing to promote the production of anti-inflammatory isoforms of proteins involved in immune regulation. Used for Inflammatory bowel disease (Crohn's disease), HIV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}